LPL and hypertriglyceridemia: Moreover, rituximab was used in a case of severe acquired autoimmune hypertriglyceridaemia resistant to traditional triglyceride-lowering therapies and it was observed to reduce plasma anti-LPL antibody levels and resulted in an improvement of hypertriglyceridaemia [101].